Previous 10 |
Represents key appointment to bolster scientific and oncology expertise as Company prepares to advance XCART platform technology Internationally renowned expert in the treatment of leukemia, myelodysplastic syndrome, multiple myeloma and other lymphoproliferative diseases, both with...
Xenetic Biosciences (NASDAQ: XBIO ): FY Net loss of ~$7.3M. More news on: Xenetic Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
- Recent transformative agreement to acquire innovative XCART platform technology positions Company to drive significant momentum - XCART expected to initially target B-cell lymphomas and has the potential to address multiple tumor types with an initial global market opportunity in Non...
FRAMINGHAM, MA / ACCESSWIRE / March 5, 2019 / Xenetic Biosciences, Inc. (NASDAQ: XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on the acquisition, research and development of novel oncology therapeutics, including next-generation cellular immunotherapies for difficu...
Nightstar Therapeutics Plc (NASDAQ: NITE ) +66% on being acquired by Biogen. More news on: Nightstar Therapeutics plc, Ascendis Pharma, China Internet Nationwide Financial Services Inc., Stocks on the move, Read more ...
Thinly traded nano cap Xenetic Biosciences (NASDAQ: XBIO ) is up 11% premarket on light volume in reaction to its acquisition of a CAR T platform technology called XCART, developed at The Scripps Research Institute (together with the Shemyakin-Ovchinnikov Institute of Bioorgani...
Innovative XCART platform with demonstrated proof of mechanism and preclinical evidence of target specificity positions Xenetic to address high value oncology market with differentiated CAR T technology XCART technology platform designed to target personalized, patient-specific tumor...
News, Short Squeeze, Breakout and More Instantly...
Xenetic Biosciences Inc. Company Name:
XBIO Stock Symbol:
NASDAQ Market:
Xenetic Biosciences Inc. Website:
Company's Board of Directors Appoint James F. Parslow to Interim Chief Executive Officer FRAMINGHAM, MA / ACCESSWIRE / May 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technolog...
Ongoing preclinical studies with multiple data readouts expected throughout remainder of 2024 Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the qu...
Continued advancement of DNase-based oncology program towards Phase 1 clinical study for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors Ended the year with $9.0 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / March 22, 2024 /...